Literature DB >> 12003252

Butyrylcholinesterase and cognitive function.

S Darvesh1, C MacKnight, K Rockwood.   

Abstract

Butyrylcholinesterase (BuChE) is expressed in brain structures involved in cognition, but the effect of selective BuChE inhibitors on human cognitive function is unknown. We report a patient whose cognitive function deteriorated following a reduction and improved following reinstitution of ethopropazine, a selective BuChE inhibitor. We suggest that, because neurons expressing BuChE may be involved in cognition, there is merit to further evaluation of selective BuChE inhibitors in treating cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12003252     DOI: 10.1017/s1041610201007876

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  6 in total

Review 1.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 2.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Gohar Mushtaq; Nigel H Greig; Jalaluddin A Khan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

Review 3.  Cholinesterases: new roles in brain function and in Alzheimer's disease.

Authors:  Ezio Giacobini
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

4.  Biochemical Analysis and Association of Butyrylcholinesterase SNPs rs3495 and rs1803274 with Substance Abuse Disorder.

Authors:  Sadaf Munir; Rabia Habib; Sliha Awan; Nazia Bibi; Arooj Tanveer; Sajida Batool; Syed M Nurulain
Journal:  J Mol Neurosci       Date:  2019-02-01       Impact factor: 3.444

Review 5.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.